Pluristem Receives Approval from Indian Ministry of Health for Use of PLX Cells in Phase II Trial for Treatment of Buerger's Disease
August 16, 2012 - (Pluristem) - "Pluristem Therapeutics, Inc., a leading developer of placenta-based cell therapies, announced today that it has received permission from the Indian Ministry of Health to proceed with a Phase II clinical trial for the treatment of thromboangiitis obliterans (Buerger's disease). This Phase II trial will be potentially followed by a larger multi-national Phase III study in the U.S., Europe and India." Read Full Article
